HSD17B13: A Potential Drug Target and Biomarker (G345275)

Target Name: HSD17B13

NCBI ID: G345275

HSD17B13

HSD17B13: A Potential Drug Target and Biomarker

HSD17B13, also known as 17-beta-hydroxysteroid dehydrogenase 13, is a gene that encodes a protein involved in the metabolism of steroids, which are a diverse family of hormones that play crucial roles in various physiological processes in the body. One of the primary functions of this protein is to convert 17-beta-hydroxysteroids, which are typically produced by the adrenal glands in response to the presence of stress or other stimuli, into 17-beta-hydroxylated steroids, which are then excreted from the body.

While HSD17B13 is a critical enzyme for the proper functioning of the adrenal glands, it is also a potential drug target and biomarker. In recent years, there has been growing interest in developing drugs that can modulate the activity of HSD17B13 and improve therapeutic outcomes in various diseases. In this article, we will explore the potential of HSD17B13 as a drug target and biomarker, as well as the research that has been conducted to study its role in human disease.

Potential Drug Target

The primary function of HSD17B13 is to convert 17-beta-hydroxysteroids into 17-beta-hydroxylated steroids. While this enzyme is critical for the normal functioning of the adrenal glands, it is also a potential drug target. One of the main reasons for this is that HSD17B13 is involved in the production of many different steroids, including cortisol, which is a key hormone that helps regulate inflammation and stress responses in the body.

Studies have shown that HSD17B13 is often reduced in individuals with autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, individuals with certain types of cancer, such as breast cancer, may also have reduced HSD17B13 levels. These observations suggest that HSD17B13 may be an attractive target for drugs that can modulate its activity and improve therapeutic outcomes in these diseases.

Biomarker

HSD17B13 is also a potential biomarker for several diseases. For example, individuals with rheumatoid arthritis may have reduced HSD17B13 levels, and may benefit from drugs that can modulate this enzyme's activity. Similarly, individuals with breast cancer may also have reduced HSD17B13 levels, and may benefit from drugs that can inhibit its activity.

In addition to its potential therapeutic applications, HSD17B13 is also a useful biomarker for tracking disease outcomes in individuals with rheumatoid arthritis and breast cancer. Studies have shown that individuals with rheumatoid arthritis and breast cancer who have HSD17B13 levels that are elevated have a more aggressive form of these diseases, while individuals with HSD17B13 levels that are lower are less likely to have these conditions. This suggests that HSD17B13 may be a useful biomarker for tracking disease outcomes in these individuals.

Research

There is a significant amount of research that has been conducted to study the role of HSD17B13 in human disease. One of the primary goals of this research is to understand how this enzyme contributes to the development and progression of various diseases.

Studies have shown that HSD17B13 is involved in the production of several different steroids, including cortisol, which is a key hormone that helps regulate inflammation and stress responses in the body. Additionally, HSD17B13 is also involved in the production of other steroids, such as androstenedione, which is a key hormone that is involved in the development and maintenance of male sexual function.

In addition to its role in the production of these steroids, HSD17B13 is also involved in the regulation of other hormones and enzymes. For example, this enzyme is

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 13

Functions: Plays a pivotal role in hepatic lipid metabolism (PubMed:29562163). In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4 (PubMed:29562163, PubMed:30415504, PubMed:32973038)

The "HSD17B13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets